Jefferies analyst Akash Tewari upgraded BioNTech SE (BNTX – Research Report) to a Buy today and set a price target of $150.00. The company’s shares closed yesterday at $123.47. Tewari covers ...

TD Cowen analyst Yaron Werber maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $85.00. The company’s shares closed last Friday at $123.40.

The BioNTech SE ADR BNTX slid 2.69% to $112.51 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and the ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. Just who are these companies and who is behind them ...

The previous Paralympic logo incorporated the Tae-Geuk ... The full-colour version on a white background is the preferred version, but a black-and-white monochrome version is also available. In ...

After hours: 16 September at 19:44 GMT-4 ...

We acknowledge Aboriginal and Torres Strait Islander peoples as the First Australians and Traditional Custodians of the lands where we live, learn and work.

A custom interior featuring ostrich skin upholstery is this 5.0’s party piece.